Securities code: 002755 securities abbreviation: Beijing Aosaikang Pharmaceutical Co.Ltd(002755) Announcement No.: 2022-018 Beijing Aosaikang Pharmaceutical Co.Ltd(002755)
Announcement on the election of employee representative supervisors of the sixth board of supervisors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Beijing Aosaikang Pharmaceutical Co.Ltd(002755) (hereinafter referred to as “the company”) was published on the designated information disclosure media of the company, securities times, securities daily and cninfo.com on January 22, 2022（ http://www.cn.info.com.cn. ）The announcement on the general election of the board of supervisors of the company (Announcement No.: 2022-007) was issued. In order to ensure the normal operation of the board of supervisors, the company held the 2022 meeting on February 16, 2022 in accordance with the company law and other laws, regulations, normative documents, the articles of association and other relevant provisions
The first employee congress in.
After careful discussion and voting, Ms. Xue Hongfang and Ms. Zhao Yanrong were elected as the employee representative supervisors of the sixth board of supervisors of the company. Their term of office is the same as that of the sixth board of supervisors. They will form the sixth board of supervisors together with the non employee representative supervisors elected by the general meeting of shareholders of the company. The resumes of Ms. Xue Hongfang and Ms. Zhao Yanrong are detailed in the annex.
The above employee representative supervisors meet the qualifications and conditions of supervisors in the company law. The number of supervisors who have served as directors or senior managers of the company in the last two years does not exceed one-half of the total number of supervisors of the company, the number of supervisors nominated by a single shareholder does not exceed one-half of the total number of supervisors of the company, and the proportion of employee representative supervisors in the board of supervisors is not less than one-third.
Documents for future reference:
Resolutions of the workers’ Congress
It is hereby announced.
Beijing Aosaikang Pharmaceutical Co.Ltd(002755) board of supervisors February 16, 2022 Annex: resume
Xue Hongfang, a member of the Communist Party of China, born in China in 1977, has Chinese nationality and no permanent residency right abroad. He served as director of the comprehensive office of Jiangsu Beijing Aosaikang Pharmaceutical Co.Ltd(002755) pharmaceutical company in January 2016 September 2017. She served as director of the bidding Office of Jiangsu Beijing Aosaikang Pharmaceutical Co.Ltd(002755) pharmaceutical company in October 2017 and served as director of Purchasing Department of Jiangsu Beijing Aosaikang Pharmaceutical Co.Ltd(002755) Pharmaceutical Co., Ltd. in January 2019. Graduated from Nanjing Normal University in 2000, majoring in English.
Xue Hongfang has no relationship with the controlling shareholder, actual controller, shareholders holding more than 5% of the company’s shares, directors, supervisors and senior managers.
Xue Hongfang does not hold shares in the company.
Xue Hongfang has not been punished by the CSRC and other relevant departments or the stock exchange in the past three years; There is no case where the case is filed for investigation by the judicial organ for suspected crime or the case is filed for inspection by the CSRC for suspected violation of laws and regulations, and there is no clear conclusion; There is no dishonest behavior, and he is not the person who is dishonest; It is not the subject of breach of faith responsibility or the object of breach of faith punishment; Meet the requirements of the company law and other relevant laws, regulations and regulations; There are no circumstances in which a person may not be nominated as a supervisor.
Zhao Yanrong, female, born in 1978, senior engineer, Chinese nationality, without permanent residency abroad, has served as the technical director of the subsidiary Jiangsu Beijing Aosaikang Pharmaceutical Co.Ltd(002755) Pharmaceutical Co., Ltd. since January 2020. He once served as deputy director of Jiangsu Beijing Aosaikang Pharmaceutical Co.Ltd(002755) production department, director of quality management department, director of Nanjing Hairun quality department and assistant to the general manager. In 2011, he obtained a master’s degree in pharmaceutical engineering from Nanjing University of technology.
Zhao Yanrong has no relationship with the controlling shareholder, actual controller, shareholders holding more than 5% of the company’s shares, directors, supervisors and senior managers.
Zhao Yanrong directly holds 4500 shares of the company.
Zhao Yanrong has not been punished by the CSRC and other relevant departments or the stock exchange in the past three years; There is no case where the case is filed for investigation by the judicial organ for suspected crime or the case is filed for inspection by the CSRC for suspected violation of laws and regulations, and there is no clear conclusion; There is no dishonest behavior, and he is not the person who is dishonest; It is not the subject of breach of faith responsibility or the object of breach of faith punishment; Meet the requirements of the company law and other relevant laws, regulations and regulations; There are no circumstances in which a person may not be nominated as a supervisor.
